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ABSTRACT  
 
Previous studies have shown that cadherin-11 (CDH11) may be involved in the 
metastatic process of osteosarcoma. The correlation of the expression levels of CDH11 
in osteosarcoma samples with the risk of disease progression and metastasis was 
examined. Real time qRT-PCR was used to quantify CDH11 expression in a set of 
newly established osteosarcoma cell lines, 11 primaries and five metastases, compared 
to the levels in 12 normal osteoblast cell lines established from healthy bone, and also in 
a set of 10 snap-frozen osteosarcoma samples. In all cases long term clinical follow-up 
data was available. The CDH11 expression level decreased gradually from the 
osteoblast to the primary cell lines (p=0.2184) and further to those established from the 
tumor metastases (p=0.0275). Importantly, the level of CDH11 expression correlated 
significantly (p=0.01) with patient survival (Kaplan-Meier survival analysis) in both 
sample sets (p=0.0128 for the cell lines, p=0.0492 for the biopsies). In conclusion, the 
results indicate that CDH11 may be useful as a prognostic marker of disease 
progression and survival in osteosarcoma. 
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INTRODUCTION 
 
Osteosarcoma is a common malignant bone-forming mesenchymal tumor, commonly 
arising in the extremities of adolescents and young adults. Although advances in 
chemotherapy have improved the survival rates during the last three decades (1, 2), 
approximately 40% of the patients do not survive, mainly due to lung metastases (3). 
Traditional prognostic indicators, such as age, gender, primary tumor location, disease-
free interval, tumor doubling time, bilaterality, respectability and number of detectable 
pulmonary metastases (4, 5) have had limited success in identifying those patients that 
need aggressive chemotherapy and those that do not. Since at present all patients receive 
pre- and post-operative chemotherapy, biomarkers that could distinguish between 
patients that would benefit from the current toxic chemotherapy and those that do not 
need chemotherapy or those that should receive other treatment alternatives instead are 
needed (6). Currently, however, few biomarkers that can be used as predictors for 
patient outcome are available. Several recent studies have identified genetic alterations 
and/or gene expression abnormalities that may be used as targets or biomarkers in 
osteosarcoma (7-13), and studies using cell lines or tumor tissue biopsies have related 
tumor gene expression profiles to response to a specific chemotherapy (10, 12, 14-16). 
However, few if any of them have made any real impact in the clinical setting. 
 
Cadherins are important cell surface molecules for cell-cell communication and 
signaling through catenin (17-19), and have been associated with tumor progression in 
several types of cancer (18, 20, 21). It is known that cadherins modulate calcium-
dependent cell adhesion, cell aggregation and migration (22, 23). Alterations in 
cadherins and catenins are known to contribute to tumor initiation, progression and 
metastasis by impacting the Wnt signaling pathway, which is a family of highly 
conserved secreted signaling molecules that regulate cell-to-cell interactions (17-19). 
Both β- and γ- catenin are involved in the oncogenic process of many tumor types (24, 
25). Over 20 types of cadherins have been discovered and characterized (22, 26), 
including cadherin11 (CDH11) which is identical to OB-cadherin and has 
approximately 60% amino acid homology with N-cadherin (27). Based on the putative 
important function of CDH11 in osteosarcoma, the expression of CDH11 might be 
useful as a prognostic marker in osteosarcoma. 
 
In this study, the potential prognostic value of CDH11 was evaluated using real time 
qRT-PCR analysis of cultured cells derived from primary and metastatic osteosarcoma 
tumors and paired normal bone, as well as on snap-frozen osteosarcoma samples. 
 
 
 
MATERIALS AND METHODS 
 
Samples 
 
A set of osteosarcoma cell lines derived from 11 untreated primary and five metastatic 
tumors and 12 paired osteoblastic cell lines established from adjacent normal bone 
tissue from patients treated and followed up at the University Clinic of Navarra, 
Pamplona, Spain, were studied. Needle biopsy specimens were disaggregated and 
cultured in αMEM (Invitrogen S.A., Barcelona, Spain) supplemented with 10% FCS 
and penicillin/steptomycin. If necessary, samples were first treated with a collagenase 
solution for 1 hour at 37°C with agitation, and the sample was filtered through 70 µm 
filters. The cells were then incubated at 37°C in a 5% CO2 atmosphere and the medium 
was replaced every three days. After the cells from the tissue explants covered the 
plastic surface, they were trypsinized and passaged. The experiments were performed 
with either first or second passages, in all cases, the cells were 90% confluent and in the 
logarithmic growth phase. The clinical data for these patients is summarized in Table I. 
 
In a second study set, 10 untreated osteosarcoma biopsy samples from patients treated at 
the Norwegian Radium Hospital, Oslo, Norway, were used and the clinical data for 
these is shown in Table II. 
 
 
RNA isolation  
 
The total RNA was isolated using TRIzol® (Invitrogen Inc., Carlsbad, CA, USA) 
according to the manufacturer’s protocol. In brief, 1 ml TRIzol was added and mixed by 
vortexing at room temperature. Two hundred µl 1-bromo-3-chloropropane (BCP) was 
added and mixed by vortexing, and then the samples were centrifuged at 4°C for 10 min 
at 14,000 rpm. 
  
The upper aqueous phase was transferred to a new microcentrifuge tube. Then, equal 
volume 100% isopropanol was added to the tube which contained the upper aqeous 
phase and mixed by vortexing, and the total RNA was precipitated at –20°C for 1 hour. 
The samples were centrifuged for 10 min at 14,000 rpm at 4°C. After removal of the 
supernatant, 500 µl 75% ethanol was added. The samples were centrifuged for 10 min at 
14,000 rpm at 4°C and the RNA pellet was air-dried and eluted with nuclease-free 
water. 
 
 
Reverse transcription (RT)  
 
Single-stranded cDNA synthesis was performed using a High-Capacity cDNA Archive 
Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
protocol. In brief, a total reaction volume of 100 µL was made including 1 µg RNA 
template, 10 µl 10x reverse transcription buffer, 4 µl 25x dNTPs, 10 µl 10x random 
primers, 5 µl 50U/µl MultiScribeTM reverse transcriptase and 1 µl RNasin® Plus RNase 
inhibitor (Promega). The RT reaction was performed at 25°C for 10 min and then 
followed by 120 min at 37°C. 
 
 
Real-time PCR 
 
Quantitative real-time PCR (qRT-PCR) was carried out using Applied Biosystems 7500 
Real-Time PCR System (Applied Biosystems). Primer/probe pairs for CDH11 (CDH11; 
Assay ID Hs00156438_m1) and internal control glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Assay ID Hs99999905_m1) were obtained from TaqMan® 
Gene Expression Assays (Applied Biosystems, Foster City, CA). A total reaction 
volume of 25 µL was made for each well, including the cDNA from each sample, 
TaqMan® Universal PCR Master Mix (Applied Biosystems) and each target 
primer/probe. The qRT-PCR analysis was performed in triplicate for each sample. PCR 
was performed at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C 
for 15 sec and 60°C for 1 min. 
  
 
Data analysis 
 
The threshold cycle (CT) value for each gene was determined by SDS software v1.2 
(Applied Biosystems). Delta-CT (∆CT) value, which is the difference between the CT 
value of the target gene and the CT value of the endogenous control gene was also 
calculated by the same software. Delta-∆CT (∆∆CT), which is the difference in the ∆CT 
value for each sample and the highest ∆CT value as a calibrator, was calculated. The      
2-∆∆CT number was used for relative quantification. 
 
The statistical analyses were performed using MedCalc® for Windows, version 9.2.0.1 
(MedCalc software, Mariakerke, Belgium). The expression level of CDH11 was 
compared among the different sample types using the Mann-Whitney test. The log-rank 
test for Kaplan-Meier survival was used to assess the association between CDH11 
expression level and survival. Statistical significance was set at p-value 0.05 or lower. 
 
 
RESULTS 
 
Real time qRT-PCR analysis indicated a tendency, although not significant (p=0.22), of 
decreased expression levels from normal osteoblastic cell cultures to primary 
osteosarcoma cell lines. Notably, comparing the CDH11 expression in the cell lines 
derived from the 11 primary and the five metastases showed a significant reduction in 
CDH11 expression level (p=0.0275) in the latter cell lines (Figure 1). 
  
The Kaplan-Meier survival plot revealed that the patients with higher CDH11 
expression in their primary tumor cell lines had significantly longer survival time 
compared to those with lower CDH11 expression (p=0.01; log-rank test) (Figure 2). 
These results were further strengthened by the data for the osteosarcoma snap-frozen 
specimens, as also in this sample set also the group with higher CDH11 expression had 
a longer survival time than the group with lower CDH11 expression (p=0.04; log-rank 
test) (Figure 3). 
 
 
DISCUSSION 
 
In this study, a strong and significant association was found between CDH11 expression 
and patient survival in both the group of paired osteosarcoma and osteoblast cell lines 
derived from samples of diseased and normal bone and the set consisted of snap-frozen 
biopsy specimens from untreated osteosarcoma patients. The significant association 
with survival was seen despite the relatively small sample size; further validation will 
require a large number of biopsy samples also obtained preferably before the beginning 
of neoadjuvant chemotherapy. The fact that osteosarcoma is a relatively rare disease 
emphasizes the need for multi-institutional collaboration to identify and validate new 
biomarkers. 
 
Our results also showed a tendency of reduced CDH11 expression in the cell lines from 
primary tumors compared to the normal osteoblast cultures, and furthermore that the 
expression level was significantly decreased in cell lines from metastases compared to 
the primary tumors (Figure 1). This supported previous data indicating that the loss of 
CDH11 may be a key event in osteosarcoma metastasis (28). Conceivably, the decrease 
in CDH11 expression may be associated with alterations in catenin expression and 
tumor invasion. Several studies have suggested that the loss or decrease of CDH11 
expression is an important event in tumor metastasis including retinoblastoma and 
osteosarcoma (20, 28-30). CDH11 is highly expressed in osteoblastic cell lines and 
plays an important role in osteoblast differentiation (31-33). However, Kashima et al. 
found anomalous expression of CDH11 in osteosarcoma, but overexpression of the gene 
suppressed pulmonary metastasis (34). In the case of osteosarcoma, it seems that loss or 
decreased CDH11 expression, much like the function of E-cadherin in many tumor 
types, contributes to tumor invasion (21, 35-40), and it has been shown that 
osteosarcoma metastasis can be prevented by restoration of the CDH11 using a mouse 
model (34). The decrease or loss of cell differentiation potential associated with the 
reduction of CDH11 expression may contribute to the oncogenic capacity of 
osteosarcoma and the sensitivity to chemotherapy (41). Furthermore, a recent report has 
demonstrated the role of CDH11 in the inflammation process in arthritis suggesting a 
potential link between inflammation, tumor invasion and metastasis in osteossarcoma 
(42). 
  
In summary, a reduced level of CDH11 expression is inversely correlated with 
osteosarcoma survival, as studied in samples obtained from two independent sources of 
tumor material with available clinical follow-up data. The loss of CDH11 may be a 
significant event in the progression and metastasis of osteosarcoma, and the results 
provide a basis to pursue future studies with a larger number of patient samples 
obtainable by a joint effort of different cancer centers. 
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Table 1. Clinical data of patients from whom cell lines of primary and metastatic         
tumors and normal bone osteoblasts were derived. 
Case Gender Age Site Histological subtype Follow-up (years) Status
1 M 22 Fibula Osteoblastic 6.8 alive 
2 M 16 Femur Osteoblastic 1.0 dead 
3 M 15 Tibia Fibroblastic 4.0 alive 
4 F 23 Femur Osteoblastic 4.0 alive 
5 M 24 Tibia Osteoblastic + chondroblastic 1.2 dead 
6 M 16 Femur Osteoblastic + fibroblastic 2.5 alive 
7 M 11 Femur Osteoblastic 1.4 alive 
8 F 21 Femur Osteoblastic 1.3 dead 
9 F 11 Femur Chondroblastic 2.2 alive 
10 F 22 Femur Osteoblastic + chondroblastic 1.9 alive 
11 M 13 Femur Osteoblastic 3.1 dead 
12 M 16 Femur Telangiectatic 1.4 alive 
13 M 16 Tibia Osteoblastic + chondroblastic 0.6 alive 
14 F 16 Femur Osteoblastic 0.4 alive 
15 F 14 Femur Osteoblastic 0.4 alive 
 
 
 
 
Table 2. Clinical data of patients from whom untreated primary snap-frozen              
tumor samples were studied. 
Case Gender Age Site Histological subtype Follow-up (years) Status
1 F 68 Femur Osteoblastic 1.2 dead 
2 F 50 Vertebra Osteoblastic 0.3 dead 
3 F 16 Tibia Osteoblastic 14.1 alive 
4 F 28 Pelvis Osteoblastic 0.4 dead 
5 F 21 Femur Osteoblastic 13.5 alive 
6 M 13 Humerus Osteoblastic 5.7 alive 
7 M 14 Tibia Osteoblastic + fibroblastic 4.7 alive 
8 M 19 Femur N/A 4.2 alive 
9 F 19 Femur Osteoblastic + telangiectatic 0.5 dead 
10 F 17 Femur Osteoblastic 3.0 alive 
 
 
 
 
 
 
Figure 1. CDH11 expression (mRNA level) in cell lines derived from normal 
osteoblasts, primary and metastatic osteosarcoma. No significant CDH11 expression 
difference was detected between normal and primary osteosarcoma cell lines (p=0.22). 
A significant decrease (p=0.02) was, however, observed in CDH11 expression when 
comparing cell lines from metastatic osteosarcoma samples and primary tumors. The 
levels of CDH11 were first normalized with housekeeping gene GAPDH. Relative gene 
expression values of CDH11 were then calculated setting the value of the lowest 
expression samples as one. 
 
 
 
 
 
Figure 2. Overall survival curves for osteosarcoma patients from whom the cell lines 
were derived, related to normalized (see legend to Fig. 1) CDH11 mRNA expression 
levels (grouped as > or < than 5) (Kaplan-Meier survival plot). Log-rank p-value =0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overall survival curves for osteosarcoma patients from whom the biopsied 
samples were obtained, related to normalized CDH11 mRNA expression levels 
(grouped as > or < than 11) in the snap frozen samples (Kaplan-Meier survival plot). 
Log-rank p-value =0.04. 
 
 
 
 
 
 
